Table 1 Baseline clinical and laboratory characteristics of patients with SA-noAKI and SA-AKI.
Variable | SA-noAKI n = 46 | SA-AKI n = 50 | P |
|---|---|---|---|
Clinical parameters | |||
Age, y | 78 (63.75, 84) | 73.5 (61.25, 83.75) | 0.479 |
Male, n (%) | 27 (58.7%) | 29 (58%) | 0.945 |
APACHE | 14.5 (10.25, 19) | 17 (13, 21) | 0.079 |
SOFA | 5 (2, 8) | 10 (6.25, 10.75) | < 0.001** |
Hypertension, n (%) | 20 (43.48%) | 29 (58%) | 0.155 |
Diabetes mellitus, n (%) | 15 (32.61%) | 21 (42%) | 0.342 |
Nephrotoxic drugs, n (%) | 39 (84.78%) | 43 (86%) | 0.866 |
Vasopressor, n (%) | 23 (50%) | 37 (74%) | 0.015* |
Diuretics, n (%) | 11 (23.91%) | 21 (42%) | 0.060 |
Tumors, n (%) | 7 (15%) | 9 (18%) | 0.715 |
Infection site | |||
Lung, n (%) | 34 (73.9%) | 22 (44%) | |
Urinary system, n (%) | 6 (13%) | 3 (6%) | |
Abdominal, n (%) | 5 (10.9%) | 18 (36%) | |
Soft tissue, n (%) | 0 (0%) | 5 (10%) | |
Central nervous system, n (%) | 1 (2%) | 1 (2%) | |
Endocarditis, n (%) | 0 (0%) | 1 (2%) | |
Septic shock, n (%) | 12 (26.09%) | 30 (60%) | 0.001** |
Hospital death, n (%) | 11 (23.91%) | 17 (34%) | 0.277 |
Laboratory parameters | |||
Scr at admission, µmol/L | 71.5 (62.25, 88) | 83.5 (71, 88.75) | 0.164 |
WBC, ×109/L | 12.17 (8.35, 15.6) | 13.23 (9.01, 19.6) | 0.294 |
Neut, ×109/L | 10 (6.14, 13.8) | 12.26 (7.15, 18.05) | 0.129 |
NLR | 10.39 (4.99, 26.92) | 18.68 (11.48, 25.94) | 0.021* |
PLT, ×109/L | 214.5 (139.75, 268.25) | 179 (120.25, 263.75) | 0.218 |
CRP, mg/L | 31.56 (9.78, 66.53) | 45.74 (31.29, 92.69) | 0.023* |
PCT, ng/mL | 0.57 (0.11, 8.29) | 14.51 (1.29, 48.15) | < 0.001** |
BUN, mmol/L | 8.15 (5.53, 14.6) | 17.05 (9.7, 21.08) | < 0.001** |
SUA, µmol/L | 323 (234.75, 418) | 474.5 (358.75, 568.5) | < 0.001** |
Fib, g/L | 3.95 (2.77, 4.62) | 4.22 (3.46, 6.6) | 0.117 |
D-D, µg/mL | 0.91 (0.44, 2.27) | 1.36 (0.89, 3.49) | 0.004** |
FDP, mg/L | 7.5 (4.2, 15.1) | 11.65 (7, 24.58) | 0.002** |
